Skip to content

Xencor Inc

XNCR

CIK 0001326732 · Pharmaceutical Preparations · Nasdaq

← back to feed
Revenue (TTM)
$101.86M
+13.7% YoY Q1 May 2026
Net Income (TTM)
−$214.19M
+60.5% YoY Q1 May 2026
EPS Diluted (TTM)
−$2.86
+65.4% YoY Q1 May 2026
Gross Margin
—
Q1 May 2026
Operating Margin
-198.1%
Q1 May 2026
Net Margin
-210.3%
Q1 May 2026
Free Cash Flow (TTM)
−$184.29M
Q1 May 2026
Cash
$14.17M
Q1 May 2026
Total Debt
$108.53M
Q1 May 2026
Shares Outstanding
74.14M sh
Q1 May 2026

Revenue & Net Income

EPS (Diluted)

Margins

Cash Flow

Revenue Growth (YoY)

Balance Sheet

Cash vs Debt

Recent filings